Skip to content
Saturday 15 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,750.11
-0.21%
DAX
26,440.31
+0.53%
CAC 40
8,636.80
-0.16%
STOXX 50
6,539.59
-0.09%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE

Astrazeneca

  • Heart patients given boost by Astrazeneca drug trials

    August 20, 2019

    A new Astrazeneca drug might help patients with heart failure, half of whom die within five years of being diagnosed, as the company this morning showed encouraging trial results. The Anglo-Swedish drugmaker said that the third phase of trials of its Farxiga medicine significantly reduced cardiovascular death or prevented heart failure from getting worse. Read [...]

  • Astrazeneca share price rises as new cancer drugs boost sales

    July 25, 2019

    Shares in Astrazeneca rose more than five per cent this morning after bumper sales of new cancer drugs fuelled a revenue rise in the second quarter. Read more: Astrazeneca promises cash to back up £12m redundancy payments for former staff The FTSE 100 pharmaceutical giant posted a 14 per cent rise in sales to $5.7bn [...]

  • GSK eyes former Astrazeneca CFO for empty chair

    July 14, 2019

    Drugmaker Glaxosmithkline is set to announce the former finance boss of Astrazeneca as its new chair to oversee the breakup of the business. GSK is preparing to appoint Jonathan Symonds as its new non-executive chair, Sky News reported earlier. Read more: GSK to split as it forms £9.8bn consumer health venture with Pfizer The announcement [...]

  • Our healthcare system is trapped in an impasse as pharmaceutical firms struggle to fund medical innovations

    May 1, 2019

    The price of technological innovations in health care has once again been brought into focus. Orkambi, a new pharmaceutical treatment for a specific type of cystic fibrosis has not been approved for availability on the NHS because its price is deemed too high. Meanwhile, there is panic at the relentless rise of fatal antibiotic-resistant infections [...]

  • Nine UK shares that tick all of Warren Buffett’s boxes

    March 26, 2019  |  City Talk

    By Kyle Caldwell from interactive investor. Looking for equity-based ISA inspiration? We run through the investment checklist of the Berkshire Hathaway chairman to identify UK shares that pass his stockpicking rules. American investor Warren Buffett is to the world of investment what Lionel Messi is to football: the greatest of his generation in the profession [...]

  • Chinese demand for medicines helps Astrazeneca return to growth

    February 14, 2019

    Strong growth in Chinese demand for new medicines helped Astrazeneca return to growth in 2018, it said today. The figures Product sales grew four per cent in 2018 compared to 2017, to hit $21bn (£16.35bn) in revenue. Fourth quarter revenue grew to $5.77bn, up five per cent year on year. Read more: Bristol-Myers Squibb to [...]

  • Trade body says hardcore of ‘repeat offenders’ are failing to listen to investor views

    December 4, 2018

    The trade body for UK investment managers has written to 32 companies on the Ftse-all share to register concern after they faced significant shareholder dissent for the last two years. The Investment Association (IA) said it was concerned that these companies had appeared on the public register, which tracks significant shareholder dissent, for the same [...]

  • FTSE 100 roundup: Today’s winners and losers

    November 16, 2018

    The FTSE 100 lost ground today, down 5.31 points at 7,032.70 just before markets closed after a turbulent start to the day when it lost as much as 0.8 per cent. All week markets have been reacting to the political fallout from Brexit as the FTSE 100 wiped out gains made late last week. Top 5 FTSE [...]

  • Astrazeneca shows disappointing results in trial of key cancer drug, shares dip

    November 16, 2018

    Shares in Astrazeneca dipped after the pharmaceutical giant revealed it had not reached the results it had hoped for from a trial of a key drug. Patients treated with the drug Imfinzi on its own and combined with the tremelimumab antibody were not significantly more likely to survive than those treated with chemotherapy alone, researchers found. [...]

  • Theresa May’s new merger powers would be a hostile takeover by the state

    October 16, 2018

    Back in July 2016, Theresa May launched her campaign for leadership of the Conservative party by promising radical action on foreign takeovers of British businesses. In the wake of Kraft’s takeover of Cadbury and Pfizer’s failed bid for AstraZeneca, May promised to defend workers and local communities from transient shareholders who, she said, were more [...]

Posts pagination

  • Previous
  • Page 1
  • …
  • Page 19
  • Page 20
  • Page 21
  • Page 22
  • Page 23
  • …
  • Page 27
  • Next

Trending Articles

  • Revolut takes flight with launch of new airport lounges

  • Grandparents fund university degrees to avoid inheritance tax net

  • Revolut chatbot goes rogue by charging users to cancel subscription

  • Brompton Bicycle sues former adviser for ‘professional negligence’

  • As It Happened: Stocks dip as oil’s ‘slowing demand’ in focus; Iran threatens to extend war

MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook